Edgewise Therapeutics, Inc. · NASDAQ:EWTX
Edgewise Therapeutics — PPMD Annual Conference 2023
10 slides from Edgewise Therapeutics's conference presentation, June 2023
Slide 1: EDG-5506: A Novel Approach to Protect Muscle in Duchenne Muscular Dystrophy
EDG-5506: A Novel Approach to Protect Muscle in Duchenne Muscular Dystrophy Joanne Donovan, MD, PhD Chief Medical Officer PPMD Annual Conference June 2023 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and interim, preliminary, topline or expected results; Edgewise’s ability to enroll patients in its uncertainties of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”). All statemen
Slide 3: The Edgewise Approach: Protect susceptible muscle fibers
The Edgewise Approach: Protect susceptible muscle fibers Some muscle fibers are more susceptible to damage due to the lack of functional dystrophin We’ve made an investigational therapy, EDG-5506 that is designed to protect these susceptible muscle fibers from damage, regardless of mutation In disea
Slide 4: How Does Dystrophic Muscle Break Down?
How Does Dystrophic Muscle Break Down? With dystrophin – fibers support each other Rest Contraction Without dystrophin – contraction causes injury Dystrophin connects contractile proteins to the membrane and surrounding matrix of fibers 4
Slide 5: EDG-5506 Protects Dystrophic Mouse Muscle
EDG-5506 Protects Dystrophic Mouse Muscle Dystrophic mouse muscle is damaged EDG-5506 protects dystrophic mouse during contraction muscle during contraction With EDG-5506, contractions don’t cause these Contraction leads to visible changes… changes Claflin, Su and Brooks. U Michigan 5
Slide 6: Initial Phase 2 Trial in Boys with Duchenne - Design
Initial Phase 2* Trial in Boys with Duchenne - Design Population Upon screening and enrollment in trial, participants assigned to dose 1, 2, or 3; randomized to treatment or placebo 3-Month Treatment Period (placebo- Approximately 27 individuals with a controlled) genetic diagnosis of DMD will be en
Slide 7: Initial Phase 2 Study in Boys with Duchenne
Initial Phase 2* Study in Boys with Duchenne A year long, two-part trial to study the safety of EDG-5506 and to identify EDG-5506 doses for further study that have the potential to best reduce muscle damage. Assessments and Visits Endpoints • Approximately 10 site visits required • Safety monitoring
Slide 8: Sites across the US will enroll for the LYNX trial
Sites across the US will enroll for the LYNX trial Sites actively recruiting • Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa • Kansas City, Kansas • Gainesville, Florida • Baltimore, Maryland • Worcester, Massachusetts • St. Louis, Missouri • Cincinnati, Ohio •
Slide 9: EDG-5506 is Being Developed for Becker and Duchenne Muscular Dystrophy
EDG-5506 is Being Developed for Becker and Duchenne Muscular Dystrophy • Taken orally, intended to preserve and improve function in Becker and Duchenne patients with any mutation • Goal to prevent damage to muscle by protecting the most susceptible muscle fibers • Potential to be used alone or in co
Slide 10: Thank You!
THANK YOU! For questions or comments please email us! studies@edgewisetx.com Visit us at https://edgewisetx.com/ https://www.facebook.com/Edgewisetx/ https://twitter.com/EdgewiseTx 10